Patent Games in the Global South: Pharmaceutical Patent Law-Making in Brazil, India and Nigeria.
- Published in:
- 2020
- Publication type:
- Book Review
Works matching DE "DRUG patent laws"
Results: 49
1
2
REGULATORY MALFUNCTIONS IN THE DRUG PATENT ECOSYSTEM.
- Published in:
- Emory Law Journal, 2020, v. 70, n. 2, p. 347
- By:
- Publication type:
- Article
3
The Supreme People's Court of China ruled on the first pharmaceutical patent linkage case after the new Patent Law.
- Published in:
- Journal of Intellectual Property Law & Practice, 2023, v. 18, n. 2, p. 74, doi. 10.1093/jiplp/jpad004
- By:
- Publication type:
- Article
4
Pain for Pfizer--claims of pregabalin patent deemed insufficient.
- Published in:
- Journal of Intellectual Property Law & Practice, 2016, v. 11, n. 8, p. 569, doi. 10.1093/jiplp/jpw087
- By:
- Publication type:
- Article
5
EARTH TO CONGRESS--THE PHARMACEUTICAL PATENT SYSTEM IS BROKEN--PHARMA PATENTS NEED THEIR OWN SET OF RULES.
- Published in:
- Southern Illinois University Law Journal, 2016, v. 41, n. 1, p. 93
- By:
- Publication type:
- Article
6
From "Glivec®" to "Prevnar 13®": How strong is the Indian drug patenting system?
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
7
The reform of drug patent system in Thailand.
- Published in:
- Thai Journal of Pharmaceutical Sciences, 2017, v. 41, n. 1, p. 30
- By:
- Publication type:
- Article
8
Should All Drugs Be Patentable?: A Comparative Perspective.
- Published in:
- Vanderbilt Journal of Entertainment & Technology Law, 2015, v. 17, n. 2, p. 295
- By:
- Publication type:
- Article
9
ANTIBODY PATENTS: USE OF THE WRITTEN DESCRIPTION AND ENABLEMENT REQUIREMENTS AT THE PATENT & TRADEMARK OFFICE.
- Published in:
- Berkeley Technology Law Journal, 2023, v. 38, n. 1, p. 1, doi. 10.15779/Z385Q4RN0D
- By:
- Publication type:
- Article
10
THIRTY YEARS OF FLAWED INCENTIVES: AN EMPIRICAL AND ECONOMIC ANALYSIS OF HATCH-WAXMAN PATENT-TERM RESTORATION.
- Published in:
- Berkeley Technology Law Journal, 2014, v. 29, n. 2, p. 1301
- By:
- Publication type:
- Article
11
THE EU PHARMACEUTICAL SECTOR: A COMMENT ON KYLE.
- Published in:
- Antitrust Law Journal, 2016, v. 81, n. 1, p. 37
- By:
- Publication type:
- Article
12
INDIA'S CRACK DOWN ON THE PRACTICE OF PHARMACEUTICAL EVERGREENING: THE 2013 NOVARTIS DECISION.
- Published in:
- UMKC Law Review, 2016, v. 85, n. 1, p. 503
- By:
- Publication type:
- Article
13
Looking for Venue in the Patently Right Places: A Parallel Study of the VENUE Act and Venue in ANDA Litigation.
- Published in:
- San Diego Law Review, 2018, v. 55, n. 1, p. 183
- By:
- Publication type:
- Article
14
TELL ME HOW IT ENDS: THE PATH TO NATIONALIZING THE U.S. PHARMACEUTICAL INDUSTRY.
- Published in:
- University of Michigan Journal of Law Reform, 2020, v. 53, n. 4, p. 755, doi. 10.36646/mjlr.53.4.tell
- By:
- Publication type:
- Article
15
PRODUCT HOPPING: ANTITRUST LIABILITY AND A PER SE RULE.
- Published in:
- Cardozo Arts & Entertainment Law Journal, 2017, v. 35, n. 3, p. 745
- Publication type:
- Article
16
What’s in a Name? The US Food and Drug Administration Issues a Guidance on the Non-proprietary Naming of Biological Products.
- Published in:
- European Journal of Risk Regulation, 2017, v. 8, n. 3, p. 559, doi. 10.1017/err.2017.46
- By:
- Publication type:
- Article
17
ESSAY: WHEN PATENTS AREN'T ENOUGH: WHY BIOLOGICS NECESSITATE DATA EXCLUSIVITY PROTECTION.
- Published in:
- 2014
- By:
- Publication type:
- Essay
18
HATCH-WAXMAN AND MEDICAL DEVICES.
- Published in:
- William Mitchell Law Review, 2014, v. 40, n. 4, p. 1407
- By:
- Publication type:
- Article
19
JUMPING INTO THE ACTAVIS BRIAR PATCH--INSIGHT INTO HOW COURTS MAY STRUCTURE REVERSE PAYMENT ANTITRUST PROCEEDINGS AND THE QUESTIONS THAT ACTAVIS LEFT UNANSWERED.
- Published in:
- William Mitchell Law Review, 2014, v. 40, n. 4, p. 1370
- By:
- Publication type:
- Article
20
THERE'S A HOLE IN MY BUCKET DEAR LIZA, DEAR LIZA: THE 30-YEAR ANNIVERSARY OF THE HATCHWAXMAN ACT: RESOLVED AND UNRESOLVED GAPS AND COURT-DRIVEN POLICY GAP FILLING.
- Published in:
- William Mitchell Law Review, 2014, v. 40, n. 4, p. 1307
- By:
- Publication type:
- Article
21
LETTING THE DEVIL RIDE: THIRTY YEARS OF ANDA SUITABILITY PETITIONS UNDER THE HATCH-WAXMAN ACT.
- Published in:
- William Mitchell Law Review, 2014, v. 40, n. 4, p. 1260
- By:
- Publication type:
- Article
22
THE HATCH-WAXMAN ACT: A PATH FORWARD FOR MAKING IT MORE MODERN.
- Published in:
- William Mitchell Law Review, 2014, v. 40, n. 4, p. 1200
- By:
- Publication type:
- Article
23
FOREWORD.
- Published in:
- William Mitchell Law Review, 2014, v. 40, n. 4, p. 1194
- By:
- Publication type:
- Article
24
A catalyst for change? Orphan drugs and the case of C atalyst v. Becerra.
- Published in:
- Journal of Generic Medicines, 2022, v. 18, n. 3, p. 194, doi. 10.1177/17411343221116086
- By:
- Publication type:
- Article
25
EXCLUDING PATENTABILITY OF THERAPEUTIC METHODS, INCLUDING METHODS USING PHARMACEUTICALS, FOR THE TREATMENT OF HUMANS UNDER TRADE RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHTS ARTICLE 27(3)(A).
- Published in:
- Hofstra Law Review, 2014, v. 43, n. 1, p. 185
- By:
- Publication type:
- Article
26
DRUGS, PATENTS, AND WELL-BEING.
- Published in:
- Washington University Law Review, 2021, v. 98, n. 5, p. 1403
- By:
- Publication type:
- Article
27
The COVID-19 Vaccine Race: Intellectual Property, Collaboration(s), Nationalism and Misinformation.
- Published in:
- Washington University Journal of Law & Policy, 2021, v. 64, p. 167
- By:
- Publication type:
- Article
28
LEAVING THE EVERGREENING PROBLEM TO THE PATENT EXPERTS - THE USPTO, THE PTAB, AND THE FEDERAL CIRCUIT.
- Published in:
- Indiana Law Review, 2021, v. 54, n. 1, p. 195, doi. 10.18060/25507
- By:
- Publication type:
- Article
29
May your drug price be evergreen.
- Published in:
- Journal of Law & the Biosciences, 2018, v. 5, n. 3, p. 590, doi. 10.1093/jlb/lsy022
- By:
- Publication type:
- Article
30
LOWERING THE "EFFICACY" THRESHOLD FOR SECTION 3(D) OF THE INDIAN PATENTS (AMENDMENT) ACT 2005: A CASE FOR A BROADER SCOPE.
- Published in:
- Emory International Law Review, 2014, v. 28, n. 1, p. 649
- By:
- Publication type:
- Article
31
NOVARTIS AG V. UNION OF INDIA: "EVERGREENING," TRIPS, AND "ENHANCED EFFICACY" UNDER SECTION 3(d).
- Published in:
- Journal of Intellectual Property Law, 2014, v. 21, n. 2, p. 223
- By:
- Publication type:
- Article
32
Ethical and Procedural Barriers to Accessing Critical Medicines in Least Developed Countries: A Look at TRIPS and the Doha Documents.
- Published in:
- Journal of Gender, Race & Justice, 2017, v. 20, n. 1, p. 209
- By:
- Publication type:
- Article
33
Overqualified and Underrepresented: Gender Inequality in Pharmaceutical Patent Law.
- Published in:
- Brigham Young University Law Review, 2022, v. 48, n. 1, p. 137
- By:
- Publication type:
- Article
34
Product Hopping.
- Published in:
- Journal of Commercial Biotechnology, 2017, v. 23, n. 2, p. 52, doi. 10.5912/jcb795
- By:
- Publication type:
- Article
35
Recent Developments in Compulsory Licensing of Pharmaceutical Patents in India.
- Published in:
- Journal of Commercial Biotechnology, 2016, v. 22, n. 2, p. 64, doi. 10.5912/jcb733
- By:
- Publication type:
- Article
36
GETTING EVEN LESS THAN WHAT THEY PAID FOR: THE PLIGHT OF GENERIC DRUG CONSUMERS UNDER THE LEVINE-MENSING DICHOTOMY.
- Published in:
- University of Colorado Law Review, 2015, v. 86, n. 1, p. 259
- By:
- Publication type:
- Article
37
CARBONS INTO BYTES: PATENTED CHEMICAL COMPOUND PROTECTION IN THE VIRTUAL WORLD.
- Published in:
- Duke Law & Technology Review, 2015, v. 14, n. 1, p. 25
- By:
- Publication type:
- Article
38
EVERGREENING AT RISK.
- Published in:
- Harvard Journal of Law & Technology, 2020, v. 33, n. 2, p. 479
- By:
- Publication type:
- Article
39
Compulsory Licensing and Anti-Evergreening: Interpreting the TRIPS Flexibilities in Sections 84 and 3(d) of the Indian Patents Act.
- Published in:
- Harvard International Law Journal, 2015, v. 56, n. 1, p. 207
- By:
- Publication type:
- Article
40
İLAÇ PATENTLERİNE KARŞI AÇILACAK MENFİ TESPİT DAVALARINDA JENERİK/EŞDEĞER İLACIN RUHSATLANDIRILMASI ŞART MIDIR?
- Published in:
- ASBU Law Journal, 2024, v. 6, n. 2, p. 2269, doi. 10.47136/asbuhfd.1567682
- By:
- Publication type:
- Article
41
HOW NON-PRODUCT-SPECIFIC MANUFACTURING PATENTS BLOCK BIOSIMILARS.
- Published in:
- Duke Law Journal, 2022, v. 71, n. 8, p. 1923
- By:
- Publication type:
- Article
42
PATENT LAW’S REPRODUCIBILITY PARADOX.
- Published in:
- Duke Law Journal, 2017, v. 66, n. 4, p. 845
- By:
- Publication type:
- Article
43
Novartis AG v. Union of India: Why the Court's Narrow Interpretation of Enhanced Efficacy Threatens Domestic and Foreign Drug Development.
- Published in:
- Boston College International & Comparative Law Review, 2016, v. 39, n. 3, p. 40
- By:
- Publication type:
- Article
44
BIOTECHNOLOGY PATENT LAW TOP TEN OF 2018 BROAD WINS, SOVEREIGNTY LOSES, AND PATENT DANCE.
- Published in:
- Akron Law Review, 2019, v. 52, n. 3, p. 637
- By:
- Publication type:
- Article
45
THE (RE)NEWED BARRIER TO ACCESS TO MEDICATION: DATA EXCLUSIVITY.
- Published in:
- Akron Law Review, 2018, v. 51, n. 4, p. 1163
- By:
- Publication type:
- Article
46
USING DATA EXCLUSIVITY GRANTS TO INCENTIVIZE CUMULATIVE INNOVATION OF BIOLOGICS’ MANUFACTURING PROCESSES.
- Published in:
- American University Law Review, 2017, v. 66, n. 3, p. 911
- By:
- Publication type:
- Article
47
CITIZEN PETITIONS: LONG, LATE-FILED, AND AT-LAST DENIED.
- Published in:
- American University Law Review, 2016, v. 66, n. 2, p. 305
- By:
- Publication type:
- Article
48
The Trans-Pacific Partnership: The Death-Knell of Generic Pharmaceuticals?
- Published in:
- Vanderbilt Journal of Transnational Law, 2016, v. 49, n. 3, p. 853
- By:
- Publication type:
- Article
49
Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans-Pacific Partnership Agreement.
- Published in:
- Medical Journal of Australia, 2015, v. 202, n. 6, p. 306, doi. 10.5694/mja14.01682
- By:
- Publication type:
- Article